Author: jcn

Demonstration test equipment integrating SOEC co-electrolysis and FT synthesisTOKYO, Feb 13, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) has conducted a demonstration of an integrated production process for synthesizing liquid fuels from carbon dioxide, water, and electricity, successfully producing liquid synthetic fuels through an integrated production system. The demonstration was conducted at MHI's Research & Innovation Center (Nagasaki District). In this process, SOEC co-electrolysis(1) is employed to produce hydrogen and carbon monoxide, which are then used as the feedstock for production of liquid synthetic fuels using Fischer-Tropsch (FT) synthesis equipment.(2) A chemical analysis of the synthesized liquid fuel confirmed that the demonstration had obtained components suitable for sustainable aviation fuel (SAF).Co-electrolysis is a process for electrolysis of both water vapor and carbon dioxide, allowing for simultaneous production of hydrogen and carbon monoxide, which are the feedstock for synthetic fuels. In addition, MHI is utilizing its proprietary technology to develop a tubular type SOEC cell stack.(3) Co-electrolysis in this SOEC cell stack is expected to simplify the process and improve economic efficiency through highly efficient electrolysis, supporting the production of cost-competitive synthetic fuels.The International Civil Aviation Organization (ICAO) has set a target to achieve net-zero CO2 emissions in the international aviation sector by 2050.(4) To meet this target, low-carbon fuels such as SAF and carbon credits are expected to account for more than 70% of the offsetting and reduction , so the demand for SAF is forecast to increase significantly worldwide. MHI aims to offer high value-added SAF production systems that combine SOEC co-electrolysis with existing FT synthesis processes.In addition to SAF, the hydrogen and carbon monoxide produced by SOEC co-electrolysis can also be used as feedstock for carbon-neutral synthetic fuels for automobiles and ships (gasoline, diesel fuel, methanol, methane), as well as city gas (methane). The many applications of SOEC co-electrolysis make it a promising technology, with potential to offer a broad range of options for the realization of a decarbonized world.Going forward, MHI will utilize the knowledge gained from this demonstration to establish and implement decarbonization technologies at an early stage, and contribute to the realization of a sustainable, carbon-neutral world.Processes and products derived from synthetic gas Road map for synthetic fuel production technology (SOEC co-electrolysis) development (1) "SOEC (Solid Oxide Electrolysis Cell) co-electrolysis" is a technology that uses solid oxides as electrolytes to simultaneously electrolyze carbon dioxide and water vapor at high temperatures. See the following Technical Review for details. https://www.mhi.com/technology/review/pdf/e623/e623040.pdf(2) "FT (Fischer-Tropsch) synthesis" is a technology to generate chemical reactions in hydrogen and carbon monoxide to produce liquid hydrocarbons. It is named after the German chemists Franz Fischer and Hans Tropsch.(3) Multiple ceramic functional membranes molded on the tubular surface. See the following Technical Review for details. https://www.mhi.com/technology/review/sites/g/files/jwhtju2326/files/tr/pdf/e621/e621030.pdf(4) For more information on the ICAO's goals, see the following. https://www.icao.int/environmental-protection/long-term-global-aspirational-goal-ltag-international-aviationAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Feb 13, 2026 - (JCN Newswire via SeaPRwire.com) - JCB International Co., Ltd., the international operations subsidiary of JCB Co., Ltd., Japan’s only international payment brand, announces its sponsorship of the NHK Symphony Orchestra Singapore Concert 2026, to be held on April 29, 2026, at the Esplanade Concert Hall in Singapore.Making the 60th anniversary of diplomatic relations between Japan and Singapore, this special concert will feature the NHK Symphony Orchestra, one of Japan’s leading orchestras, in its first performance in Singapore in 24 years. The program includes works by prominent Japanese composer Yuzo Toyama, together with Benjamin Britten’s Four Sea Interludes from Peter Grimes, a selection inspired by the theme of the “sea” that connects Japan and Singapore, promising a richly varied and compelling musical experience.Takumi Takahashi, Executive Vice President, JCB International Co. Ltd. said: "We are truly delighted to support the NHK Symphony Orchestra’s concert, presented by one of Japan’s most renowned and distinguished orchestras. This year marks the 60th anniversary of the establishment of diplomatic relations between Japan and Singapore, and the concert we are sponsoring is a special event commemorating this milestone. Through this sponsorship and various other initiatives, we hope to help make the SJ60 celebration even more vibrant."Concert DetailsOrganizerNHK Symphony OrchestraDateApril 29, 2026VenueEsplanade – Theatres on the Bay, Concert Hall (Singapore)Websitehttps://www.esplanade.com/whats-on/festivals-and-series/series/classics/nhk-symphony-orchestra-special-concert About JCBJCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 71 million merchants around the world. JCB Cards are now issued mainly in Asian countries and territories, with more than 175 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide. For more information, please visit: www.global.jcb/en/ContactAnna TakedaCorporate CommunicationsTel: +81-3-5778-8353Email: jcb-pr@info.jcb.co.jp Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Tokyo and Kawasaki, Japan, Feb 12, 2026 - (JCN Newswire via SeaPRwire.com) - Lockheed Martin (NYSE: LMT) and Fujitsu Limited, a Japanese multinational leader in information technology solutions, finalized the first purchase order for a critical component of Japan’s Aegis System Equipped Vessel (ASEV)’s SPY-7 radar antenna.A signing ceremony between the two companies formalized Fujitsu as a supplier for the SPY-7 Subarray Suite Power Supply Line Replaceable Unit (PS LRU), marking a significant step in co-production and Japanese industrial collaboration.“Lockheed Martin’s collaboration with Fujitsu cements our commitment to establishing a Japan‑based supply chain for ASEV’s SPY‑7 radar that will keep the fleet mission‑ready for decades,” said Chandra Marshall, Vice President and General Manager at Lockheed Martin. “This is a continuation of our contribution and Fujitsu’s shared commitment to strengthening Japan’s defense capabilities.” In May 2025, the two companies signed a memorandum of understanding to establish Fujitsu as a source for the SPY-7 PS LRU. Lockheed Martin's SPY-7 solid-state radar technology allows users to respond to evolving threats with advanced detection and tracking capabilities, while enabling simultaneous engagement of multiple targets.SPY-7 provides several times the performance of traditional SPY-1 radars and is being utilized by domestic and international customers around the world, including Japan. SPY-7 is also interoperable with other radars and platforms, including the Aegis Combat System.“Fujitsu is honored to commence the mass production of the PS LRU, a critical component of the SPY-7 radar system and contribute to the strengthening of Japan’s defense sector domestic production and maintenance infrastructure,” said Kenichiro Miyazaki, SVP, Head of National Security Business Unit, Fujitsu Limited. “Fujitsu remains committed to solidifying Japan’s long-term defense capabilities and further enhancing Japan’s national security through this partnership with Lockheed Martin.” Securing a Japan‑based SPY‑7 supplier for the ASEV fleet highlights Lockheed Martin and Fujitsu’s joint dedication to elevating Japan’s defense strength and technological edge.As the security environment in the Indo-Pacific region continues to evolve, the collaboration between Lockheed Martin and Japan will remain a critical factor in enabling regional security and prosperity.Through a true partnership between Lockheed Martin and Japan’s defense community, both nations are strengthening Japan’s role in the Indo-Pacific and the broader regional security architecture. About Lockheed MartinLockheed Martin is a global defense technology company driving innovation and advancing scientific discovery. Our all-domain mission solutions and 21st Century Security® vision accelerate the delivery of transformative technologies to ensure those we serve always stay ahead of ready. More information at Lockheedmartin.com.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsLockheed Martin Asia – Shorbani Roy, TEL: +813-4563-8000 E-mail: shorbani.roy@global.lmco.comU.S. – Audrey Spiteri, TEL: +1-203-402-9478 E-mail: audrey.m.spiteri@lmco.comFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Tokyo and Kawasaki, Japan, Feb 12, 2026 - (JCN Newswire via SeaPRwire.com) - Meiji Co., Ltd. and Fujitsu Limited today announced the start of a pilot project towards the social implementation of rRAFU™ [1] (Rapid Risk Assessment Tool for Future Undernutrition Status), the world's first [2] indicator to predict future risks of malnutrition and frailty (developed by Meiji.) The pilot will focus on residents aged 60 and over in Kawasaki City, Kanagawa Prefecture.This pilot project incorporates a self-care support app, built by Meiji and Fujitsu, that combines rRAFU with Fujitsu's AI-driven behavioral change support service. The project will verify the effectiveness of rRAFU and the app's ability to promote behavioral change in frailty prevention among participants in the pilot.Both companies aim to contribute to frailty prevention among the elderly by enabling early identification of malnutrition and frailty risks, which are often difficult to self-diagnose. Through the self-care support app utilizing rRAFU, both companies seek to encourage lifestyle improvements, including diet and exercise, at an early stage before risks become apparent, and will leverage the knowledge gained from this pilot project for future social implementation, aiming to prevent frailty in later life and contribute to people's healthy and secure lives.OverviewTarget participants: Approximately 240 people aged 60 and over residing in Kawasaki City.Period: February 2026 to June 2026In this pilot project, after registering for the self-care support app, participants will undergo a future malnutrition and frailty risk assessment using rRAFU, and the results will be provided to them. Based on the assessment results, participants will select lifestyle improvement plans, such as diet and exercise, that they find manageable. Fujitsu's AI technology will encourage the implementation of these plans via email, tailored to each participant's activity characteristics, thereby supporting their consistent engagement in daily life.After approximately three months, the project will evaluate the feasibility and sustainability of the actions taken and the resulting changes. Through this pilot project, participants are expected to deepen their understanding of future malnutrition and frailty risks, which were previously difficult to perceive, and to find motivation to initiate and sustain lifestyle improvements.Roles of each company:Meiji provides the rRAFU indicator for assessing future malnutrition and frailty risk and is responsible for planning mechanisms to translate assessment results into lifestyle improvements, as well as the overall project planning. Fujitsu is responsible for the development and operation of the AI-powered app.Figure: Overall picture and service flow overviewAbout the self-care support appThis app was built by Meiji and Fujitsu, building upon Fujitsu's AI-driven behavioral change support service and incorporating Meiji's rRAFU indicator for assessing future malnutrition and frailty risk.Participants answer the simple 13 questions of rRAFU to understand their future risks and then select and implement lifestyle improvement plans, including diet and exercise, in their daily lives. The app utilizes Fujitsu's AI technology to support participants in recording and reviewing their actions, enabling them to engage in self-care without undue burden.About rRAFUrRAFU is an indicator that allows individuals to understand their future (approximately two years ahead) risk of malnutrition and frailty by answering 13 simple questions across four domains closely related to malnutrition and frailty risk: "nutrition-related," "eating habits," "physical activity," and "food-related quality of life (QOL)." A total score based on the answers evaluates the presence of potential malnutrition and frailty risks. This indicator was developed through research led by Professor Shoji Shinkai of Kagawa Nutrition University, together with collaborating institutions.BackgroundIn Japan, the aging population has made frailty and malnutrition significant societal challenges, and both can often lead to a need for long-term care. Malnutrition is difficult to self-diagnose, and by the time it is recognized, frailty may have already progressed.Previous long-term care prevention measures have largely focused on interventions after physical decline becomes apparent. There has been a lack of mechanisms to identify future risks early and connect individuals to personalized improvement actions. Furthermore, merely presenting risks often fails to sustain behavioral change.Meiji, through its long-standing research in food and nutrition, has focused on the importance of self-care that can be easily incorporated into daily life. Meiji and Fujitsu initiated this pilot project with the goal of visualizing the risk of future malnutrition and frailty and enabling individuals to choose and commit to actions that prevent frailty at an early stage, thereby contributing to a healthier aging society.[1] rRAFU:In Japan, the trademark and copyright for this evaluation index are held by Meiji Holdings Co., Ltd. and Meiji Co., Ltd.[2] World's first: As of January 2026, based on Meiji's research of publicly available information.About MeijiMeiji’s purpose is to enrich people’s lives and contribute to a more sustainable society by delivering deliciousness, health, and peace of mind through food.. As a trusted partner in the fields of food, approximately 10,000 employees are working to address some of the greatest health and nutrition challenges facing humanity. Our wide range of products and services, including dairy products, confectionery, nutritional foods, and prepared foods, support healthy living and a rich dietary culture every day. www.meiji.comAbout FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

KAWASAKI, Japan, Feb 12, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu today announced that it will start manufacturing “Made in Japan” sovereign AI servers designed to support mission-critical operations. Production is slated to begin in March 2026 at the Fujitsu Group's Kasashima Plant in Japan. Fujitsu will also start production of Made in Japan servers equipped with Fujitsu's high-performance, energy-efficient FUJITSU-MONAKA (1) processor within fiscal year 2026 (ending March 31st 2027). Geopolitical shifts, rising cyber threats, and regulatory demands have made critical information protection an urgent global imperative. In Japan, as the designation of specified essential infrastructure service providers progresses under the Economic Security Promotion Act, system risk management and digital sovereignty are paramount for customers that are dealing with critical infrastructure. This includes minimizing data leakage, ensuring autonomous operation, complying with local laws, maintaining transparent security, and controlling technology to guarantee comprehensive IT integrity.OverviewBy promoting the following initiatives, Fujitsu aims to enhance the transparency of traceability, security risk, device operation visibility, and operational autonomy for mission-critical and sovereign domains.1. Provision of servers equipped with leading-edge processors Fujitsu will start manufacturing Made in Japan sovereign AI servers, featuring NVIDIA HGX B300 and NVIDIA RTX PRO 6000 Blackwell Server Edition GPUs in March 2026Production will also include Made in Japan servers equipped with FUJITSU-MONAKA processors, incorporating confidential computing technology for enhanced security against threats 2. Integrated domestic production systemThe Fujitsu Group's Kasashima Plant will produce the servers, utilizing its expertise from manufacturing the supercomputer Fugaku and other highly-reliable serversIntegrated domestic production system, covering everything from printed circuit board to device assembly (starting June and March 2026 respectively), ensures full traceability and transparency for enhanced sovereignty3. Expanding strategic partnershipsThe Fujitsu Group will expand its collaboration with Super Micro Computer, Inc. to consistently provide planning, development, manufacturing, sales, and maintenance for the AI servers4. Global expansionThese Made in Japan server products are scheduled for deployment in both the Japanese and European markets[1] FUJITSU-MONAKA:This new technology applied to FUJITSU-MONAKA is based on results obtained from a project subsidized by the New Energy and Industrial Technology Development Organization (NEDO).About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

BOSTON, Feb 11, 2026 - (ACN Newswire via SeaPRwire.com) - Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with laboratory-confirmed acute viral infection. The Bioxyytran Trial reports complete elimination of viral load in 100% of patients at day 7 versus placebo (p=.001).The completed Phase 2 clinical study was a randomized, double-blind, placebo-controlled, dose-optimization trial evaluating orally administered ProLectin-M in subjects with acute viral infection. The study enrolled 38 subjects, all of whom completed the study. Subjects were randomized to receive one of three ProLectin-M dose levels or a matching placebo, administered over a seven-day treatment period.Viral shedding was assessed using RT-PCR analysis of nasopharyngeal swabs collected at predefined timepoints, with viral clearance defined as non-detection of viral RNA below established PCR thresholds.The study design, endpoints, and duration confirmed Bioxytran’s earlier randomized, placebo-controlled Phase 2 trial, which demonstrated statistically significant reductions in viral load by Day 7, early clearance as soon as Day 3, and no observed viral rebounds during a 14-day post-treatment observation period. The current trial further refined dose selection of four tablets per day and evaluated the reproducibility of rapid viral clearance using the same core virologic assessment methodology.Topline Viral Clearance ResultsFollowing database lock and unblinding, treatment-wise analyses demonstrated the following outcomes:Complete elimination of viral load in 100% of treated subjects by Day 7, compared to the placebo group (p = .001)No viral rebounds observed in the treated population during the 14-day post-treatment observation periodThese results indicate rapid and sustained viral clearance in subjects treated with ProLectin-M.Viral Clearance Timing (All Subjects)Across the full study population:Day 3: 1 of 38 subjects demonstrated non-detection of viral sheddingDay 5: 16 of 38 subjects demonstrated non-detection of viral sheddingDay 7: 38 of 38 subjects demonstrated non-detection of viral sheddingThe study was designed to evaluate viral clearance kinetics and inform dose selection for future late-stage clinical development.“The study design of seven days reflects real-world applications for treating acute viral diseases, with the objective of demonstrating a statistically meaningful reduction in viral load by Day 7,” said Dr. Leslie Ajayi, Chief Medical Officer of Bioxytran. “The results demonstrate that viral clearance occurred more rapidly than anticipated, with a significant proportion of treated subjects achieving viral non-detection by Day 3 and complete clearance by Day 7.”“What continues to distinguish ProLectin-M as a broad-range antiviral drug is its novel mechanism of action,” Dr. Platt continued. “Rather than targeting viral replication inside the cell, our galectin antagonist is designed to interfere with viral entry at the cell surface. This extracellular approach may reduce reliance on immune activation and represents a fundamentally different strategy in antiviral therapy. We believe these results further support the potential of carbohydrate-based therapeutics and the emerging field of Glycovirology.”Next StepsBased on these results, Bioxytran plans to advance regulatory discussions to support late-stage clinical development and evaluate ProLectin-M across additional viral indications consistent with its broad-spectrum antiviral profile.About Bioxytran, Inc.Bioxytran, Inc. is a clinical-stage biotechnology company developing novel carbohydrate-based therapeutics targeting significant unmet medical needs in virology and other disease areas. The Company’s lead program, ProLectin-M, is being developed as a potential broad-spectrum antiviral therapeutic.For more information, please visit www.bioxytraninc.com.Investor & Media Contact:Bryan Feinberg / AmplifiXZephyr@amplifiX.net Company Contact:david.platt@bioxytraninc.com(617) 510-2539Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding the performance of the technology described herein, the interpretation of clinical trial results, regulatory plans, and future development activities. Forward-looking statements are generally identified by words such as “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements include these terms. Such statements are subject to significant risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed or implied. These risks are described in Bioxytran’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other filings made from time to time. Bioxytran undertakes no obligation to update or revise any forward-looking statements, except as required under applicable securities laws. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Toyota City, Japan, Feb 11, 2026 - (JCN Newswire via SeaPRwire.com) - Toyota Motor Corporation (Toyota) announced that it will expand its battery electric vehicle (BEV) lineup in North America as part of its multi-pathway approach toward achieving a carbon-neutral society. As part of this effort, Toyota Motor North America (TMNA), Toyota's North American business entity, premiered a new BEV model of the three-row SUV Highlander on February 11 (JST; February 10 PST) in Ojai, California. Sales in North America are expected to begin in late 2026.Highlander BEV (North American model)Toyota is committed to product- and region-centered management with the aim of making ever-better cars. In developing powertrain systems to achieve carbon neutrality, Toyota is rolling out a variety of mobility solutions under its multi-pathway approach, offering electrified vehicle options tailored to meet customer needs in each country and region around the world.To steadily advance its multi-pathway approach in the North American market, Toyota will add a BEV model as a key option for the Highlander. Production will take place at Toyota Motor Manufacturing Kentucky (TMMK) as the fourth model in its BEV lineup, following the bZ*1, TOYOTA C-HR*2, and bZ Woodland*3.*1North American name for the bZ4X*2North American name for the TOYOTA C-HR+ (Europe)*3North American name for the bZ4X Touring Highlander BEV (North American model)The Highlander has earned strong support from families as a three-row SUV that handles everything from city driving to outdoor adventures, thanks to its spacious interior and excellent off-road performance. Since the first generation launched in the United States in 2001, cumulative sales have exceeded 3.6 million units*4. With the addition of this BEV model, Toyota aims to further evolve the Highlander in its pursuit of a carbon-neutral society.The lithium-ion battery lineup includes a 76.96kWh*5*6 capacity specification designed for urban driving, such as shopping trips, and a 95.82kWh*5*6 capacity specification aimed at improving cruising range for customers who enjoy long-distance travel and outdoor activities. Together with front-wheel drive (FWD) and all-wheel drive (AWD) types, a wide range of options are available to customers. In addition to incorporating a high-capacity battery and improving eAxle efficiency, the 95.82kWh*5*6 specification has a development target cruising range of up to 320 miles*7 (AWD).Battery preconditioning*8 is included, with a development target of rapid charging in approximately 30 minutes*9 under cold conditions by maintaining the battery at an optimal temperature for charging.Main specifications (development targets) for the Highlander BEV (North American model)DrivelineFWDAWDLength(in)198.8Width(in)78.3Height(in)67.3Wheelbase(in)120.1Cruising range(miles)287270320Battery capacity(kWh)76.96*695.82*6 *4U.S. cumulative sales, 2001-2025*5Development target*6Measured in accordance with IEC standard 62660-1.*7Development target value when driving in EPA mode*8A function that adjusts the battery temperature before rapid charging*9Approximate time required to charge from approximately 10% to 80% of full capacity using a 150kW (350A) rapid charger in an environment with an outside temperature of -10°C.Moving forward, Toyota will continue to address customer needs in each region and contribute to carbon neutrality by developing a variety of options―including HEVs, PHEVs, and FCEVs―while striving to make ever-better cars."Achieving zero, and adding new value beyond it"As part of efforts to pass our beautiful "Home Planet" to the next generation, Toyota has identified and is helping to solve issues faced by individuals and overall society, which Toyota calls "Achieving Zero," hoping to help reduce the negative impacts caused by these issues to people and the environment to zero. Additionally, Toyota is also looking "Beyond Zero" to create and provide greater value by continuing to diligently seek ways to improve lives and society for the future.About Beyond Zero: https://global.toyota/en/mobility/beyond-zero/Toyota Motor Corporation works to develop and manufacture innovative, safe and high-quality products and services that create happiness by providing mobility for all. We believe that true achievement comes from supporting our customers, partners, employees, and the communities in which we operate. Since our founding over 80 years ago in 1937, we have applied our Guiding Principles in pursuit of a safer, greener and more inclusive society. Today, as we transform into a mobility company developing connected, automated, shared and electrified technologies, we also remain true to our Guiding Principles and many of the United Nations' Sustainable Development Goals to help realize an ever-better world, where everyone is free to move.SDGs Initiatives: https://global.toyota/en/sustainability/sdgs/ Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Feb 10, 2026 - (JCN Newswire via SeaPRwire.com) - Ahead of the start of the 2026 FIA*1 Formula One World Championship (F1TM) season, Honda works partner Aston Martin Aramco Formula One™ Team (AMAF1), has unveiled the livery for its new F1 machine, the AMR26. Powered by the Honda F1 power unit, the RA626H, the AMR26 will take on the challenge of F1, the pinnacle of automobile racing.The AMR26 is the first F1 machine designed for the team by Adrian Newey, AMAF1 Managing Technical Partner and Team Principal, and it is being developed at the AMR Technology Campus, at AMAF1 headquarters in Silverstone, the U.K.Together with AMAF1, Honda will conduct pre-season testing in Bahrain for a total of six days, — February 11-13 and 18-20 — and make necessary adjustments before taking on the season-opening race at the Australian Grand Prix on Sunday, March 8, 2026.*1 Fédération Internationale de lʼAutomobileComments by Adrian Newey, Managing Technical Partner and Team Principal, Aston Martin Aramco Formula One™ Team“2026 is a rare moment in Formula One because, for the first time, the chassis and power unit regulations have changed together. With brand-new regulations, the best philosophy is never immediately obvious, and your understanding evolves as the car develops. With the AMR26 we’ve taken a holistic approach: it’s not about one standout component, but how the full package works together. The focus has been on strong fundamentals, development potential, and a car that Lance and Fernando can extract performance from consistently.”Comments by Koji Watanabe, President of Honda Racing Corporation (HRC)“Getting ready for the start of the 2026 F1 season where we will compete with a completely new chassis and power unit, Honda/HRC has been developing the RA626H, the new power unit which will power the AMR26, the new machine of our works partner, Aston Martin Aramco Formula One™ Team. As one united team with AMAF1, we are delighted to take this first step into a highly demanding, yet most exciting challenge in the world of motorsport.”Aston Martin Aramco Formula One™ Team drivers No.DriverAgeNationalityBest F1 result in 202514Fernando Alonso44Spain10th18Lance Stroll27Canada16th Fernando Alonso Lance Stroll ＜For reference＞2026 F1 race calendar RoundRace dateGrand Prix*LocationRace start timeLocal timeJapan timeRound 1March 8AustraliaMelbourne15:0013:00Round 2March 15ChinaShanghai15:0016:00Round 3March 29JapanSuzuka14:0014:00Round 4April 12BahrainSakhir18:0000:00 (Apr.13)Round 5April 19Saudi ArabiaJeddah20:0002:00 (Apr.20)Round 6May 3MiamiMiami16:0005:00 (May 4)Round 7May 24CanadaMontreal16:0005:00 (May 25)Round 8June 7MonacoMonaco15:0022:00Round 9June 14Barcelona-CatalunyaBarcelona15:0022:00Round 10June 28AustriaSpielberg15:0022:00Round 11July 5Great BritainSilverstone15:0023:00Round 12July 19BelgiumSpa-Francorchamps15:0022:00Round 13July 26HungaryBudapest15:0022:00Round 14August 23NetherlandsZandvoort15:0022:00Round 15September 6ItalyMonza15:0022:00Round 16September 13SpainMadrid15:0022:00Round 17September 26AzerbaijanBaku15:0020:00Round 18October 11SingaporeSingapore20:0021:00Round 19October 25United StatesAustin15:0005:00 (Oct. 26)Round 20November 1MexicoMexico City14:0005:00 (Nov. 2)Round 21November 8BrazilSão Paulo14:0002:00 (Nov. 9)Round 22November 21Las VegasLas Vegas20:0013:00 (Nov. 22)Round 23November 29QatarLusail19:0001:00 (Nov. 30)Round 24December 6Abu DhabiYas Island17:0022:00*Short names for each Grand Prix. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Japan, Feb 10, 2026 - (JCN Newswire via SeaPRwire.com) - Honda Motor Co., Ltd. (Honda) today announced that the company will make organizational and operational changes, effective April 1, 2026, in order to sustainably offer the joy and freedom of mobility all around the world through its mobility products and services.In 2020, with the aim of solidifying its existing business while preparing for future growth, Honda separated two key research and development functions — the development of production models and research on future technologies — enabling each group to focus on its roles. This initiative generated solid results including contribution to Honda business and the enhancement of technological competitiveness.With the global business environment surrounding Honda changing faster than expected, the company will further strengthen its ability to grasp market and technology trends more accurately and deliver the original technologies and new value of Honda to the market at the optimal timing. Toward this goal, Honda will make changes to the organizational structure of the Automobile Development Operations and the Automobile Operations.Moreover, the Motorcycle and Power Products Operations will also undergo some organizational changes to ensure future growth. Details of the organizational changes effective April 1, 20261) Consolidation of automobile R&D functions at Honda R&D Co., Ltd.The R&D functions of the Automobile Development Operations and the SDV Business Development Unit within the Automobile Operations will be transferred to Honda R&D Co., Ltd., the R&D subsidiary of Honda.Since 2020, the two key research and development functions — the development of production models and research on future technologies — have been operated separately so that each group can focus on its roles. However, in order to further enhance the strengths of its products, Honda will make organizational changes to build a structure where the entire process — from the selection of technology themes through product market launches — is viewed as one integrated flow to drive the entire process at speed, while flexibly responding to the changes in business environment. Through this change, Honda R&D will be further advanced as a R&D organization capable of continuing to create compelling products, through which Honda will further increase its competitiveness.2) Reorganization of Automobile Operations The Automobile Business Strategy Unit and Sales Unit will be reorganized into the Business Strategy Unit and Regional Business Unit, which will be newly created effective April 1, 2026. In addition, the business functions currently being served by the SDV Business Development Unit will be reorganized into the new Business Strategy Unit, and the SDV Business Development Unit will be disbanded.Through these organizational changes, for the earliest improvement of the profitability of its automobile business, Honda will 1) enhance its product planning and sales capabilities in light of market dynamics and customer needs, and 2) strengthen the competitiveness of its products from the mid- to long-term perspectives. 3) Reorganization of Motorcycle and Power Products Operations As the electrification strategy for motorcycle and power products business has transitioned into the execution stage, sales, business strategy and product development functions currently being served separately for electrification business and ICE (internal combustion engine) business will be integrated. Through the integrated management of electrification and ICE business, Honda will pursue optimal allocation of resources and continue initiatives toward carbon neutrality, while striving to ensure the continuous creation of increasingly competitive products. Through these organizational changes, Honda will further accelerate ongoing initiatives for its corporate transformation through electrification and new value creation, through which Honda will strive to establish a more distinctive presence as “a company society wants to exist” even in the era of electrification and intelligent technologies. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Feb 10, 2026 - (JCN Newswire via SeaPRwire.com) - KS Energy Co., Ltd. ("KS Energy"), a renewable energy business company and Hitachi, Ltd. (TSE:6501, “Hitachi”) agreed on February 6 to collaborate on the development and operation of an Extra-High Voltage Grid Battery Energy Storage System*1 within Kumamoto Prefecture, as well as the development and operation of power trading businesses. Hitachi will provide project development support for KS Energy's development of the project and jointly promote the development and operation of this battery energy storage system (tentative name)*2 . Additionally, KS Energy will also explore the introduction of a power trading support system planned for development by Hitachi.This initiative will support stable power supply in the Kyushu region and contribute to achieving carbon neutrality.*1 Extra-High Voltage Grid Battery Energy Storage System: Large-scale battery storage facilities directly connected to the power grid (such as transmission lines) with a capacity of 2,000 kW or more.*2 Power Trading Support System: A power trading support system for operators managing large-scale grid-connected storage batteries. It supports traders' daily operations comprehensively—from bid planning and market transactions to submitting plans to OCCTO—across both the supply-demand adjustment market and the wholesale electricity market. System development also incorporates collaboration with other companies, such as bid plan optimization services. This contributes to improved profitability through trading based on optimal bid plans and streamlines routine daily tasks like plan submission.BackgroundRenewable energy generation fluctuates due to weather changes and other factors, significantly impacting the power supply-demand balance. Particularly in the Kyushu region, where renewable energy adoption is advancing, output curtailment occurs frequently when generation exceeds demand. Securing balancing power to stabilize the power grid is an urgent priority. Furthermore, as the policy framework for promoting renewable energy shifts from the FIT (Feed-in Tariff) system to the FIP (Feed-in Premium) system, power generators are now required to develop their own electricity trading capabilities to formulate strategies for selling electricity in the power market. Against this backdrop, the importance of "aggregators" – entities that consolidate and control energy resources to adjust supply-demand balance – is growing. They are expected to contribute to the effective utilization and stable supply of renewable energy by engaging in both the electricity market and the power trading market.To address this situation, KS Energy, established in January 2024 with full investment from Higo Bank, Ltd. (part of the Kyushu Financial Group), has adopted a policy to contribute to stabilizing power supply as a regional energy company, aiming to make the entire Kyushu region a leading area for renewable energy circulation. Meanwhile, Hitachi has a long history in the power sector, providing a wide range of advanced solutions from energy storage systems to transmission and distribution infrastructure and grid protection devices.Through this collaborative effort, both companies will combine their respective strengths. By developing and operating energy storage facilities and engaging in power trading, they aim to achieve carbon neutrality in the Kyushu region.Initiative DetailsKS Energy and Hitachi have decided to jointly develop and operate battery energy storage system in the Kyushu region. This initiative contributes to stabilizing local power supply by charging and discharging in response to electricity demand-supply balance, thereby providing balancing power.1. Nation's First Extra-High Voltage Battery Energy Storage System project launched by a regional bank group This marks the first instance nationwide of a bank subsidiary's renewable energy business company undertaking a grid energy battery business in the extra-high voltage range. Through this initiative, we aim to contribute to stable power supply. Additionally, KS Energy is considering managing the power trading for the storage facility in-house. The plan involves handling the entire operational process: forecasting electricity market prices, creating power generation (charging/discharging) plans for the batteries, controlling the storage facility, and monetizing through market transactions. In the future, leveraging its operational expertise in storage facilities and collaborating with Higo Bank, KS Energy will enhance support for power generators and provide financing support to storage facility developers. This will enable the delivery of services extending beyond the financial sector, promote efficient electricity usage within local communities, and contribute to achieving regional carbon neutrality and decarbonization.2. Joint Promotion of Project Development from the Early Stage Leveraging Hitachi’s extensive experience in battery energy storage systems, Hitachi and KS Energy will jointly promote the development of energy storage facilities. The Hitachi Group will work together to promote project development through to operational launch. This includes cooperation from grid connection application discussions with transmission and distribution operators to applications and procedures with relevant ministries and agencies, provision of business feasibility evaluation information, supply of Hitachi Energy-manufactured PCS, and project management covering equipment design, procurement, and installation. Hitachi will sustainably support KS Energy's stable operations of the storage facility.3. Collaboration in Power Trading Business To stably utilize rapidly expanding renewable energy, the need for aggregation functions that balance electricity supply and demand is growing. KS Energy is considering introducing Hitachi's planned power trading support systemto achieve efficient energy resource utilization and aim for stable power supply. Under Hitachi's Lumada 3.0 initiative, the company is deploying "HMAX by Hitachi" (hereinafter HMAX), a next-generation AI solution suite that tackles the most complex challenges facing social infrastructure. This is achieved by combining vast data from both physical and digital assets with advanced AI enhanced by Hitachi's unique deep domain knowledge. In the electric power trading area as well, Hitachi will realize services that optimize the operation of storage battery assets and maximize market value, and aim to deploy them as HMAX.Future DevelopmentsKS Energy and Hitachi will collaborate to achieve both the mainstreaming of renewable energy as a primary power source and stable supply through the development of battery energy storage system and enhanced aggregation functions, working together toward realizing regional carbon neutrality.Overview of Grid-Connected Storage FacilityStorage Facility Name : (Provisional name) KSE Kumamoto Battery Energy Storage SystemStorage Facility Location (Planned) : Within Kumamoto PrefectureRated Output/Rated Capacity (Planned) : 50,000 kW / 112,880 kWhScheduled Start of Operation : January 2029 Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO and CAMBRIDGE, Mass., Feb 10, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, which was accepted in January 2026, has been designated for Priority Review by the National Medical Products Administration (NMPA) of China.The Priority Review and Approval Procedure was implemented by the NMPA with the aim of accelerating research, development and launch of new medicines that have significant clinical value. Under this Procedure, the assessment period is expected to be shortened.If approved, the SC-AI of 500 mg (two 250 mg injections) could be used to administer a once-weekly dose at home from the initiation of treatment, as an alternative to the current IV administration every two weeks in a hospital setting. The potential approval of SC-AI would expand the option for patients and care partners to receive LEQEMBI treatment at home. The injection time for each autoinjector (250 mg injection) is approximately 15 seconds. The SC formulation also has the potential to reduce healthcare resources associated with IV dosing, such as preparation for infusion and nurse monitoring, while streamlining the overall AD treatment care pathway.Eisai estimates that there were 17 million patients with MCI or mild dementia due to AD in China in 2024, which is expected to increase with the aging of the population. LEQEMBI was launched in China in June 2024 and has been delivered in the private market. Furthermore, LEQEMBI has been included in the newly introduced “Commercial Insurance Innovative Drug List” (Chinese: 商业健康保险创新药品目录), which took effect in January 2026, under new Chinese government policies that support the development of and access to innovative medicines. Based on the Commercial Insurance Innovative Drug List, Commercial insurance companies will develop insurance products covering LEQEMBI.Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. In China, Eisai will distribute the product and conduct information provision activities through specialized Medical Representatives.MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@Eisai.comBiogen Inc.Madeleine Shin+1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+ 1-781-464-2442IR@biogen.com About LEQEMBI (generic name: lecanemab, Chinese brand name: 乐意保)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 7 countries including the U.S., China, the UK, and others, and applications have been filed in 7 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. A Supplemental Biologics License Application (sBLA) for initiation treatment was accepted in January 2026. The sBLA has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of May 24, 2026. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In January 2026, the Biologics License Application (BLA) for the subcutaneous formulation was accepted in China. In December 2025, Lecanemab (IV) has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China. Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About ProtofibrilProtofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of soluble Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.1 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.2About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.For more information, visit https://www.eisai.com/news/2026/pdf/enews202608pdf.pdf Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Feb 9, 2026 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701) will exhibit at MWC Barcelona 2026, the world's largest mobile-related exhibition, held from Monday, March 2 to Thursday, March 5, 2026, in Barcelona, Spain.NEC booth renderingUnder the theme of "Building an AI-Native Society," NEC will showcase its initiatives for the social implementation of hardware and software to realize advanced communications in an AI-Native society in the Beyond 5G/6G era.On March 2, the first day of the exhibition, Dr. Juergen Quittek, Head of NEC Laboratories Europe, will participate as a panelist in a session titled "AI and Us: What Are We Really Building Toward?" He will discuss the expanding applications of AI, drawing on NEC's efforts in this field.Furthermore, the NEC exhibition booth will showcase the latest vRAN-compatible Radio Units (RUs) for enhancing the efficiency of 5G networks, low-power RU amplifier modules, AI automation for realizing network automation through software, and initiatives for energy efficiency.About the Panel SessionDate & Time: Monday, March 2, 10:45 – 11:45 (CET)Venue: Hall 6 Johnson StageTitle: Conference "AI and Us: What Are We Really Building Toward?"Speaker: Dr. Juergen Quittek, Head of NEC Laboratories EuropeURL: https://www.mwcbarcelona.com/agenda/sessions/5965-ai-and-us-what-are-we-really-building-towardExhibition BoothLocation: Hall 2 Stand 2B18Exhibits: 5G/6G vision, latest vRAN-compatible 5G base station equipment, power amplifier modules for 5G base station equipment, optical device products, AI automation, etc.Going forward, NEC will continue to contribute to the realization of an AI-Native society by implementing advanced communication equipment and virtualization technologies throughout the world.About NECThe NEC Group leverages technology to create social value and promote a more sustainable world where everyone has the chance to reach their full potential. NEC Corporation was established in 1899. Today, the NEC Group’s approximately 110,000 employees utilize world-leading AI, security, and communications technologies to solve the most pressing needs of customers and society.For more information, please visit https://www.nec.com, and follow us on LinkedIn and YouTube. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

HONG KONG, Feb 9, 2026 - (ACN Newswire via SeaPRwire.com) – CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883) is pleased to announce a triumph in winning two prestigious awards as 2026 unfolds, recognizing its cybersecurity and continuous innovation capabilities. CITIC Telecom CPC’s AI-driven Security Operations Centre (AI SOC) is honored “Best AI SOC Service Provider” in “IT PRO Corporate Choice Award 2025” from the well-known IT media . In addition, two security experts of CITIC Telecom CPC have won two accolades in “Internet and Cloud Services” sector of “Cyber Security Professional Awards 2025” organized by the Hong Kong Police Force (Cyber Security and Technology Crime Bureau, CSTCB).Mr. Brook Wong, Chief Executive Officer of CITIC Telecom CPC, said, “2026 marks the 25th anniversary of CITIC Telecom CPC. Our tagline “Innovation Never Stops for 25 Years. Empowering a Smarter Future” embodies 25 years of continuous innovation, driving the creation of a more secure and highly efficient digital future. We strive to enhance our solutions to address the evolving needs of our customers and drive innovation in an ever-changing landscape. We empower enterprises to leverage innovative security solutions to elevate operational efficiency, supporting their “Going Global” and “Coming to China” efforts with tailored strategies, and being the trusted DICT service partner of multinational corporations and enterprise customers. We are honored to receive the “Best AI SOC Service Provider” Award and the “Cyber Security Professional Awards 2025”, a testament to our enduring commitment to cybersecurity innovation and the technical expertise of our talented professional team, driving groundbreaking solutions development through technological innovation.”CITIC Telecom CPC proudly presents the following accolades:“IT PRO Corporate Choice Award 2025”- “Best AI SOC Service Provider”“Cyber Security Professional Awards 2025” - 2 Accolades in “Internet and Cloud Services” sectorCITIC Telecom CPC clinches “Best AI SOC Service Provider” of“IT PRO Corporate Choice Award 2025”Garners IT PRO Corporate Choice Award 2025CITIC Telecom CPC’s AI SOC has been bestowed with the "Best AI SOC Service Provider" of the ‘IT PRO Corporate Choice Award 2025” for the first time. This award honors CITIC Telecom CPC's customer-focused innovative security solutions that address enterprises’ evolving needs in an increasingly complex cyber threats environment. It also serves as a testament to CITIC Telecom CPC's unwavering dedication to delivering top-tier AI-driven security services, which are widely valued by enterprise customers across different industries. CITIC Telecom CPC’s cutting-edge SOC technologies have been highly acclaimed in the industry. The company was honored one of the top three most trusted Security Operations Centers (SOCs) in Hong Kong according to the “IT PRO Corporate SOC Survey[1]” conducted by in April 2025, recognizing its technical expertise and market leadership in security operations.Leveraging groundbreaking and robust AI technologies, AI SOC significantly enhances the overall efficiency of SOC. As the core of AI SOC, SIEM-MiiND is a self-built and managed intelligent security information and event management (SIEM) platform. It utilizes big data and intelligent technologies to boost the detection capabilities of AI SOC, optimize rule sets, improve response capabilities, provide AI-powered chatbot and user-friendly security dashboard, enabling cost-effective and robust security protection for enterprises, and reshaping the future cybersecurity model. Two Cybersecurity Experts Win Two Accolades in Cyber Security Professional Awards 2025Organized by the Hong Kong Police Force (CSTCB), Cyber Security Professional Awards 2025 aims to recognize outstanding industry talent, foster innovation, and strengthen public-private collaboration to jointly enhance Hong Kong’s cybersecurity. Two security experts of CITIC Telecom CPC received two accolades in “Cyber Security Professional Awards 2025” Thomas KT Wong, Director of Security Services Delivery & Operation, and Sung Liu, Security Specialist of CITIC Telecom CPC received Silver and Merit Awards respectively in the “Internet and Cloud Services” sector of “Cyber Security Professional Awards 2025”. Both of them have over 10 years of network security experience. Thomas KT Wong is instrumental in managing the SOCs of CITIC Telecom CPC. He leads a team of security experts to provide 24/7 security monitoring and incident response services, thereby safeguarding enterprise cybersecurity. Sung Liu is responsible for core technologies support, providing comprehensive and practical security solutions to address enterprise pain points. The two awardees have extensive industry experience, profound knowledge and technical expertise, facilitating CITIC Telecom CPC in maintaining its competitive edges in the cybersecurity market and further reaffirming its professionalism and commitment to the cybersecurity sector.About CITIC Telecom CPCWe are CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883), serving multinational enterprises the world over by addressing their specific ICT requirements with highly scalable tailored solutions built upon our flagship technology suites, comprising TrueCONNECT™ private network solutions, TrustCSI™ information security solutions, DataHOUSE™ cloud data center solutions, and SmartCLOUD™ cloud computing solutions.With the motto “Innovation Never Stops,” we leverage innovative technologies to boost technology empowerment (+AI). Embracing AI, AR, Big Data, IoT, and other cutting-edge emerging technologies we aim to unlock technical potential. By integrating deep learning and intelligent data analysis technologies, we transform these technologies into data empowerment (AI+) generative applications, reshaping the Intelligence Operation Journey of enterprises.With our Global-Local capabilities, we are committed to providing our customers with one-stop-shop ICT solutions with superior quality. Having a worldwide footprint across nearly 160 countries and regions, including Asia, Europe and America, Africa, the Middle East, and Central Asia, our global network resources connect nearly 170 points of presence (POPs), 60+ SD-WAN gateways, 20 Cloud service centers, 30+ data centers, and three dedicated 24x7 Security Operations Centers (SOCs). We are certified with a series of international certifications, including SD-WAN Ready, ISO 9001, 14001, 20000, 27001, and 27017, to ensure our services compliance with international standards and resources for enterprises. We offer local professional services, superior delivery capabilities as well as exceptional customer experience and best practices through our global presence and extensive industry know-how, becoming a leading integrated intelligent ICT service provider to enterprise customers.For more information, please visit www.citictel-cpc.com.Media Contacts:Catherine YuenCITIC Telecom CPC(852) 2170 7536 Email: catherine.yuen@citictel-cpc.com[1] The survey was conducted online by IT PRO via email questionnaire to more than 12,000 mid to senior-level executives in local enterprises in April 2025. Source (Chinese only): https://itpromag.com/2025/05/16/it-pro-soc-result Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO//SINGAPORE, Feb 9, 2026 - (JCN Newswire via SeaPRwire.com) - JCB International Co., Ltd., the international operations subsidiary of JCB Co., Ltd., Japan's only international payment brand, today announced a new collaboration with RESORTS WORLD AT SENTOSA PTE. LTD. (RWS), targeted at Japanese tourists. The partnership with RWS is designed to enhance the travel experience for Japanese visitors to Singapore.Located on Sentosa, Singapore’s premier resort island, Resorts World Sentosa is one of the nation’s leading integrated lifestyle destinations, welcoming millions of local and international visitors annually across its attractions, dining, entertainment and lifestyle offerings. This collaboration aims to curate meaningful experiences that enhance every stage of the visitor journey for Japanese guests.JCB and RWS today launched exclusive privileges for Japan-issued JCB cardmembers visiting Singapore’s leading integrated resort. Under this collaboration, eligible JCB cardmembers booking online will enjoy:1. Up to 20% savings on selected attractions and accommodation experiences; and2. Dining and retail privileges at participating outlets within RWS attractions.These privileges are designed to enhance every stage of the visit, from iconic attractions to hotel stay, delivering seamless, rewarding experiences for international guests. Full details, as well as terms and conditions including participating outlets are available on https://www.rwsentosa.com/en/promotions/jcb.“Our launch of this programme comes at an opportune time, amid a steady rise in Japanese tourist arrivals to Singapore. Visitor numbers from Japan in 2025 have exceeded 2024 while remaining below pre-pandemic levels. Through collaboration with leading attractions such as RWS, we aim to offer Japanese travellers more compelling reasons to visit, enjoy, and extend their stay in Singapore,” said Hiroko Michishita, Managing Director, JCB International Asia Pacific.Jenny Wang, Acting Senior Vice President, Resort Sales and Marketing, RWS, commented: “We are pleased to partner with JCB to deepen our engagement with Japanese travellers and strengthen RWS’s presence in the Japan market. Through this collaboration, we aim to welcome JCB cardmembers to experience Singapore and RWS through a curated range of attractions, dining and lifestyle experiences, complemented by exclusive privileges and joint marketing initiatives between two trusted brands. Beyond this campaign, our partnership with JCB reflects our longer-term commitment to building sustained relevance in Japan, positioning Resorts World Sentosa as Asia’s leading lifestyle destination that continues to inspire repeat visitation, deeper engagement and enduring brand affinity among Japanese guests.”JCB cardmembers can learn more via the following page:https://www.specialoffers.jcb/en/promotion/yokosoJCB_Singapore/About JCBJCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 71 million merchants around the world. JCB Cards are now issued mainly in Asian countries and territories, with more than 175 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide. For more information, please visit: http://www.global.jcb/en/ContactAnna TakedaCorporate CommunicationsTel: +81-3-5778-8353Email: jcb-pr@info.jcb.co.jp Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Feb 9, 2026 - (JCN Newswire via SeaPRwire.com) - Anime Tokyo Station is an anime exhibition site focused on Japanese anime content, which has developed a devout fan base around the world. The facility attracts visitors of all ages and has welcomed 253,236 guests from Japan and overseas (as of January 18, 2026).©Taiki Kawakami, Fuse, KODANSHA/ “Ten-Sura”Anime Tokyo Station regularly hosts special exhibitions for popular anime. From February 21 (Sat.) to May 24 (Sun.), 2026, it will hold the “That Time I Got Reincarnated as a Slime” Special Exhibition.This popular TV anime first aired in 2018 and has now reached its third season. The story follows Satoru Mikami, an office worker who is suddenly reincarnated as a slime in another world after being caught up in an incident. Taking on the name Rimuru Tempest, he embarks on a series of adventures in this new realm. At present, in addition to the fourth season of the TV anime that is slated to air, a second theatrical release, “That Time I Got Reincarnated as a Slime: The Movie – Tears of the Azure Sea,” is also scheduled for release this February.This special exhibition will look back on the story through the third season of the TV anime, featuring life-size character panels, character introductions, and a mosaic depicting the scene where Rimuru and Veldora become friends, created using stills from the anime. Visitors can also enjoy interactive digital content, creating an experience unique to Anime Tokyo Station where they can fully immerse themselves in the world of the series.Come to Anime Tokyo Station and experience what the “That Time I Got Reincarnated as a Slime” Special Exhibition has to offer.“That Time I Got Reincarnated as a Slime” Special ExhibitionExhibition OverviewThe TV anime “That Time I Got Reincarnated as a Slime” first aired in 2018 and has grown into a beloved series spanning three seasons, with a fourth season slated to air. Additionally, “That Time I Got Reincarnated as a Slime: The Movie – Tears of the Azure Sea” is scheduled for release as well. This special exhibition will feature exhibits that allow visitors to experience the world of the series, including recreations of iconic scenes such as when Rimuru and Veldora become friends, as well as introductions to popular characters.Highlights of the ExhibitionExhibitsLife-size character panelsA mosaic depicting the scene where Rimuru and Veldora become friends, created using stills from the animeA look back at the story through stills and memorable lines Hands-on areasAR photo spot: Take a commemorative photo with Rimuru! And moreDatesFebruary 21, 2026 to May 24, 2026*Exhibition content is subject to change without notice. Details will be announced on the official website.Special exhibition URL: https://animetokyo.jp/en/archives/events/events56/About the SeriesWhat is “That Time I Got Reincarnated as a Slime”?“That Time I Got Reincarnated as a Slime” is an isekai anime series following a protagonist who is reincarnated as a slime in another world, using the skills he acquires along with his wits and courage to gather allies. The first season of the TV anime aired on TOKYO MX and other channels from October 2018 to March 2019.In 2021, TV anime Season 2 Part 1 aired from January to March, followed by the spin-off comic adaptation “Slime Diaries: That Time I Got Reincarnated as a Slime” from April to June, and TV anime Season 2 Part 2 from July to September, making for nine consecutive months of broadcasts. Then, on November 25, 2022, “That Time I Got Reincarnated as a Slime: The Movie – Scarlet Bond” was released nationwide, becoming a major hit with over one million admissions and box office revenue of 1.4 billion yen in Japan.To commemorate the 10th anniversary of the web novel “That Time I Got Reincarnated as a Slime,” the Tensura 10th Project launched on February 20, 2023. As part of this project, the all-new three-episode animation “That Time I Got Reincarnated as a Slime: Visions of Coleus” began streaming on November 1, 2023. On December 16, 2023, the series’ first large-scale event, That Time I Got Reincarnated as a Slime: Tensura 10th Live, was held at Mori no Hall 21 in Matsudo. Furthermore, the third season of the TV anime aired from April to September 2024. Following the final episode of Season 3, production of a second theatrical film and Season 4 of the TV anime was announced. “That Time I Got Reincarnated as a Slime: The Movie – Tears of the Azure Sea” is set to release on February 27, 2026.The original manga “That Time I Got Reincarnated as a Slime” (serialized in Kodansha’s Monthly Shonen Sirius / Manga: Taiki Kawakami, Original story: Fuse, Character design: Mitz Vah) is a comic adaptation of the popular web novel of the same name by Fuse, which surpassed 1 billion page views on the user-generated novel publishing website “Shosetsuka ni Naro.” The combined worldwide circulation of the manga, novels, and spin-off works has exceeded 56 million copies (as of June 2025).* “Shosetsuka ni Naro” is a registered trademark of HinaProject Inc.Tensura Portal Site: ten-sura.comOfficial X: @ten_sura_anime / Official Instagram: tensura_official / Official TikTok: @ten_sura_animeVenue OverviewName:Anime Tokyo Station (also known as "Anime Tokyo")Location:Floors B1 to 2F of Tokyu East 5 (2-25-5 Minami-Ikebukuro, Toshima-ku, Tokyo)*4 minutes on foot from Ikebukuro StationHours:11:00 a.m. to 7:00 p.m. (last admission: 6:45 p.m. / Special exhibitions close: 6:30 p.m.)Closed: Mondays*If Monday falls on a holiday, the venue will be open on Monday and closed on the following dayNew Year's holiday periodMay be closed on other daysPlease check the venue website before coming.Admission fee:FreeWebsite:https://animetokyo.jp/en/SNS：X｜https://x.com/animetokyo_info (@animetokyo_info)Instagram｜https://www.instagram.com/animetokyostation/(@animetokyostation)YouTube｜https://www.youtube.com/channel/@AnimeTokyoStationInquiries regarding this press releasePublic Relations Office of "Anime Tokyo Station" (Kyodo PR)Contact person: Miri YasudaE-mail: animetokyo-pr@kyodo-pr.co.jp Press release: https://www.acnnewswire.com/docs/doc/20260209.pdf Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

All-new Versa VanTOKYO, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) announced that Mitsubishi Motors Philippines Corporation (MMPC), a subsidiary of Mitsubishi Motors in the Philippines, began sales of the all-new Versa Van on February 6. The model is an OEM-supplied commercial vehicle by Nissan Motor Co., Ltd. (hereafter, Nissan).The all-new Versa Van offers five-row seating for up to 15 passengers and features a spacious interior optimized for transporting people, supporting a wide range of commercial applications, including shuttle services. Powered by a 2.5-liter inline four-cylinder diesel engine, the model delivers strong torque from the moment of acceleration, ensuring confident performance even when carrying many passengers or driving on steep inclines. With this new model, Mitsubishi Motors aims to strengthen its commercial vehicle lineup in the Philippines and meet customer needs alongside the existing L300 model.As Alliance partners, Mitsubishi Motors and Nissan are pursuing global collaboration in areas such as joint development and production of next-generation pickup trucks, as well as joining forces to drive business expansion in electrified vehicles. The OEM supply of the all-new Versa Van by Nissan for the Philippine market represents a tangible outcome of this collaboration. Mitsubishi Motors has also begun supplying Nissan with the Rogue Plug-in Hybrid for North America and the Navara for Oceania and has been supplying the Livina to the Philippine market since 2022 — an initiative that improves plant utilization and complements model lineups, building a mutually beneficial partnership. Furthermore, Mitsubishi Motors will receive OEM supply of an all-new EV model derived from Nissan’s new LEAF in 2026 and will introduce the model to the North American market in the latter half of the year.Mitsubishi Motors will continue to leverage diverse partnerships to expand its product lineup, strengthen regional operations, and accelerate initiatives that enhance profitability.About Mitsubishi MotorsMitsubishi Motors Corporation (TSE:7211) — a member of the Alliance with Renault and Nissan — is a global automobile company based in Tokyo, Japan, which has about 28,000 employees and a global footprint with production facilities in Japan and the ASEAN region. Mitsubishi Motors has a competitive edge in SUVs, pickup trucks and plug-in hybrid electric vehicles, and appeals to ambitious drivers willing to challenge convention and embrace innovation. Since the production of our first vehicle more than a century ago, Mitsubishi Motors has been a leader in electrification — launched the i-MiEV, the world’s first mass-produced electric vehicle in 2009, followed by the Outlander PHEV, the world’s first plug-in hybrid electric SUV in 2013. With a target of increasing the sales ratio of electrified vehicles to 100% by 2035, Mitsubishi Motors will deliver models that embody Mitsubishi Motors-ness and contribute to the realization of a carbon-neutral society.For more information on Mitsubishi Motors, please visit the company's website at https://www.mitsubishi-motors.com/en/ Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Sony Corporation (Sony), Mitsubishi Corporation, ADEKA CORPORATION , CHIMEI Corporation, ENEOS Corporation, Formosa Chemicals & Fibre Corporation, Hanwha Impact Corporation, Idemitsu Kosan Co., Ltd., Mitsui Chemicals, Inc., Neste Corporation, Qingdao Haier New Material Development Co., Ltd., SK Geo Centric Co., Ltd., Toray Industries, Inc., and Toray Advanced Materials Korea Inc. have jointly established the world’s first global supply chain consisting of fourteen companies across five countries and regions for the production of renewable plastics*2 that can be used in Sony’s high-performance audio-visual products. The various plastic materials manufactured through this supply chain are slated for use in Sony’s products that will be launched worldwide.＜Overview of the Entire Supply Chain＞(1) Production of renewable naphtha — Neste Corporation / (2) Production of renewable styrene monomer — Idemitsu Kosan Co., Ltd. / (3) Production of renewable polystyrene resin — Formosa Chemicals & Fibre Corporation / (4) Production of renewable para-xylene — SK Geo Centric Co., Ltd. / (5) Production of renewable para-xylene — ENEOS Corporation / (6) Production of renewable terephthalic acid — Hanwha Impact Corporation / (7) Production of renewable PET resin — Toray Advanced Materials Korea Inc. / (8) Production of renewable bisphenol-A — Mitsui Chemicals, Inc. / (9) Production of renewable polycarbonate (PC) resin — CHIMEI Corporation / (10) Production of renewable flame retardants — ADEKA CORPORATION / (11) Production of renewable PC/ABS resin — Qingdao Haier New Material Development Co., Ltd./ (12) Molding manufacturers / (13) Design and manufacturing of finished products — Sony CorporationHigh-performance products such as audio-visual equipment involve a wide variety of plastics, resulting in a complex supply chain that makes it difficult to visualize and manage the entire flow from raw materials. Additionally, plastic components that require high performance in terms of flame resistance and optical properties cannot be fully replaced with plastics produced through material recycling*3, hindering the further reduction of virgin fossil-based plastics in such products.To address these challenges, the fourteen companies collaborated to visualize the existing supply chain for Sony’s products, and created a new supply chain that enables the production of multiple types of renewable plastics from biomass resources with a mass balance approach*4. This allows Sony to proactively source raw materials for its products with the quality and properties equivalent to virgin fossil-based plastics. Defining the supply chain helps the companies track and document GHG (Greenhouse Gas) emissions data over the supply chain in a verifiable way, allowing participating companies to leverage the data to advance efforts to reduce their carbon footprint going forward.This initiative involving wide-ranging partners is part of the ‘Creating NEW from reNEWable materials' project, jointly launched by Sony, which aims to achieve zero usage of virgin fossil-based plastics through the introduction of renewable plastics, and Mitsubishi Corporation.Sony, Mitsubishi Corporation, and the supply chain partners will continue to actively promote the introduction of renewable plastics for high-performance products such as audio-visual products.About ProjectProject Introduction Video：https://youtu.be/3ba3t356sHI[About Sony Corporation]Sony Corporation is a wholly-owned subsidiary of Sony Group Corporation, responsible for the Entertainment, Technology & Services (ET&S) business. With the mission to "create the future of entertainment through the power of technology together with creators", we aim to continue to deliver Kando* to people around the world. Sony is actively promoting initiatives to reduce environmental impact as part of the Sony Group’s "Road to Zero" environmental plan, which aims for zero environmental impact by 2050. In this project, Sony will oversee the entire supply chain and promote the utilization of renewable plastics in our products. https://www.sony.co.jp/en/[About Mitsubishi Corporation]Mitsubishi Corporation (MC) is an integrated trading and investment company that develops and operates businesses across multiple industries together with its global network. MC has eight Business Groups that operate across virtually every industry: Environmental Energy, Materials Solution, Mineral Resources, Urban Development & Infrastructure, Mobility, Food Industry, Smart-Life Creation, and Power Solution. Through these eight Business Groups, MC’s activities have expanded far beyond its traditional trading operations to include project development, production, and manufacturing operations, working in collaboration with our trusted partners around the world. In this project, MC plays a comprehensive role in overseeing the supply chain, including credit delivery management, and promoting the introduction of renewable plastics into Sony products. https://www.mitsubishicorp.com/jp/en/[About ADEKA CORPORATION]ADEKA CORPORATION is a manufacturer of valuable materials with over 100 years of history. ADEKA aims to realize a sustainable society by globally expanding valuable materials that enrich people's lives, such as polymer additives that enhance plastic functionality, advanced semiconductor materials, environmental materials, food products, and agrochemicals. In this project, we manufacture flame retardants with biomass characteristics assigned using a mass balance approach. https://www.adeka.co.jp/en/[About CHIMEI Corporation]CHIMEI is a leading high-performance materials company that designs and manufactures advanced polymer materials, synthetic rubbers, and specialty chemicals, delivering innovative and sustainable solutions for industries worldwide. With a commitment to circularity, environmental responsibility, and close client collaboration, CHIMEI supports and partners with global companies to elevate product performance while jointly minimizing environmental impact. In this project, CHIMEI produces polycarbonate resin (PC) with assigned biomass characteristics using a mass balance approach. https://www.chimeicorp.com/en-US[About ENEOS Corporation]At ENEOS Corporation, our network has grown to about 12,000 ENEOS branded service stations across Japan. ENEOS is expanding business to accommodate energy transitions into sources like hydrogen and Synthetic Fuels in addition to petroleum and petrochemical products produced and manufactured at refineries and factories at various locations in Japan. The ENEOS Group aims to achieve both a stable supply of energy and materials and the realization of a carbon-neutral society, based on its commitment of “Supporting ‘today’s normal,’ taking the lead for ‘tomorrow’s normal.’” In this project, ENEOS manufactures paraxylene (PX) with assigned biomass characteristics using a mass balance approach. https://www.hd.eneos.co.jp/english/[About Formosa Chemicals & Fibre Corporation (FCFC)]FCFC is a comprehensive chemical company that manufactures petrochemical products, synthetic fibers, and plastics. FCFC implements a circular economy to achieve both environmental protection and industrial development, working on the development of green chemicals and the expansion of reusable materials. In this project, FCFC manufactures polystyrene (PS) with assigned biomass characteristics using a mass balance approach. https://www.fcfc.com.tw/[About Hanwha Impact Corporation]Hanwha Impact is a leading petrochemical and investment company, engaged in chemical products and next-generation energy solutions. Hanwha Impact aims to achieve a sustainable society through developing eco-friendly energy solutions and fostering future innovative technologies. In this project, Hanwha Impact produces high-purity terephthalic acid (PTA) with assigned biomass characteristics using a mass balance approach. https://www.hanwhaimpact.com/[About Idemitsu Kosan Co., Ltd.]The Idemitsu Group is engaged in the development, manufacture, and sales of a wide variety areas of Petroleum, Basic Chemicals, High-Performance Materials, Power/Renewable Energy, and in a variety of fields. Idemitsu Kosan is taking on the challenge of an energy transition to help realize a carbon-neutral and circular society by 2050. In the Basic Chemicals business, we are promoting the use of biomass feedstocks and advancing chemical recycling initiatives. In this project, Idemitsu Kosan produces styrene monomer (SM) using a mass balance approach. https://www.idemitsu.com/en/index.html[About Mitsui Chemicals, Inc.]Mitsui Chemicals is a chemical manufacturer that provides solutions for achieving a sustainable society, offering a wide range of products and services from basic chemicals to high-performance materials. Aiming for carbon neutrality by 2050, the company is working to reduce GHG emissions (Scope 1 and 2) and to maximize its contribution to GHG reductions throughout the entire product life cycle. In this project, Mitsui Chemicals produce biomass-derived bisphenol A (BPA) using the mass balance approach. https://jp.mitsuichemicals.com/en/index.htm[About Neste Corporation]Neste (NESTE, Nasdaq Helsinki) creates solutions for mitigating climate change and accelerating a shift to a circular economy. The company is the world’s leading producer of sustainable aviation fuel (SAF), renewable diesel, and renewable and circular solutions for the chemical and plastics industries. In this project, NESTE supplies renewable naphtha made from waste cooking oil and other renewable raw materials. https://www.neste.com/[About Qingdao Haier New Material Development Co., Ltd.]Haier is a global home appliance manufacturer originating, offering a wide range of products including refrigerators and washing machines. Haier New Materials, a subsidiary of the Haier Group, reduces carbon emissions and promotes the construction of a sustainable society by recycling regenerated plastic materials from disassembled home appliances. In this project, Haier produces recycled PC/ABS blended with a flame retardant with assigned biomass characteristics. https://www.haierdawn-plastics.com/[About SK Geo Centric Co., Ltd.]SKGC is a leading chemical company, offering petrochemical products such as olefins, aromatics and polymers. SKGC is upgrading our portfolio to provide more sustainable products in consumer’s daily lives. In this project, SKGC manufactures paraxylene (PX) with assigned biomass characteristics using a mass balance approach. https://www.skgeocentric.com/[About Toray Industries, Inc.]Toray Industries, Inc., is a global leader in advanced materials innovation, comprising more than 300 affiliated companies and approximately 48,000 employees worldwide. Since 1926, Toray Industries have continuously expanded our business portfolio—from Fibers & Textiles, to Resins & Chemicals, Films, Electronics & Information Materials, Carbon Fiber Composite Materials, Pharmaceuticals & Medical Products, as well as Water Treatment & Environment. April 2026 marks the 100th anniversary of Toray’s founding. In line with our Corporate Philosophy, “Contributing to society through the creation of new value with innovative ideas, technologies and products,” we will commit to delivering fundamental solutions to global-scale challenges. https://www.toray.com/ [About Toray Advanced Materials Korea Inc.]TAK is a comprehensive chemical manufacturer, offering various products from daily life to high-end industries. With consistent investing and innovation, TAK provides material solutions for climate crisis. In this project, TAK manufactures PET resin and film with assigned biomass characteristics using a mass balance approach. https://www.torayamk.com *1 In the manufacturing of audio-visual products, this initiative is regarded as a “world’s first” in that it visualizes the entire supply chain from raw materials to finished products and converts raw materials to biomass-based materials at mass-production scale.(Based on research conducted by Mitsubishi Corporation. At the time of announcement in Feb. 2026)*2 Plastics made from renewable biomass resources instead of fossil resources.*3 A method of reusing plastic materials by returning used plastics to their original form through physical processes such as crushing, cleaning, and melting, rather than discarding them.*4 This is a method of allocating the characteristics of specific raw materials, such as biomass resources, to a portion of the product based on the input amount of those materials when they are mixed with non-specific raw materials during the distribution and processing stages from raw materials to products.* "Sony", "SONY" logo and any other product names, service names or logo marks used in this press release are registered trademarks or trademarks of Sony Group Corporation or its affiliates. Other product names, service names, company names or logo marks are trademarked and copyrighted properties of their respective owners and/or licensors.* Visual content in this release may be removed without prior notice due to licensing or copyright reasons.* Kando is a Japanese word that roughly translates to the sense of awe and emotion you feel when experiencing something beautiful and amazing for the first time.MaterialityBased on the Three Corporate Principles, which serve as MC’s core philosophy, MC has continued to grow together with society by contributing to the sustainable development of society through its business activities while pursuing value creation. While continuously creating Shared Value guided by the Materiality, a set of crucial societal issues, MC will continue to strengthen its efforts towards sustainable corporate growth. Guided by this Materiality, MC will continue to strengthen its efforts towards sustainable corporate growth. Out of the six material issues relating to “Realizing a Carbon Neutral Society and Striving to Enrich Society Both Materially and Spiritually”, this project’s activities particularly support “Contributing to Decarbonized Societies” and “Promoting Stable, Sustainable Societies and Lifestyles.”Inquiry RecipientMitsubishi CorporationTelephone:+81-3-3210-2171 Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO and SHANGHAI, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, “Henlius”) announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly® in the EU) in Japan.Serplulimab, a novel anti-PD-1 monoclonal antibody developed by Henlius, is reported to possess a unique binding mode that differs from existing anti-PD-1 antibodies. 1 In China, it has been approved for indications such as squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), non-squamous non-small cell lung cancer (nsNSCLC), and esophageal squamous cell carcinoma (ESCC). In the EU, it has been approved for ES-SCLC. It is the world's first anti-PD-1 antibody to be used as a first-line treatment for ES-SCLC.In Japan, Henlius is currently conducting a Phase II bridging clinical trial for ES-SCLC, and plans to submit an application for fiscal year 2026 based on the results of this trial as well as the Phase III clinical trial data that supported approvals for this indication in China and Europe. Furthermore, a Phase III multi-national clinical trial for non-high-frequency microsatellite instability (non-MSI-High) metastatic colorectal cancer is underway, with development for new indications also planned.In Japan, it is estimated that there are approximately 13,000 patients diagnosed with ES-SCLC and about 28,000 patients diagnosed with non-MSI-High metastatic colorectal cancer, both of which are considered to have high unmet medical needs. 2,3,4,5Under the terms of this agreement, Eisai will obtain exclusive rights to commercialize serplulimab in Japan. In addition to ES-SCLC and non-MSI-High metastatic colorectal cancer, Henlius plans to also conduct a clinical trial for perioperative gastric cancer in Japan, and will assume the responsibilities of the Marketing Authorization Holder.Eisai will pay Henlius a contractual upfront payment of USD 75 million (approximately JPY 11.6 billion*), in addition to regulatory milestone payments of up to USD 80.01 million (approximately JPY 12.4 billion), and sales milestone payments of up to USD 233.3 million (approximately JPY 36.2 billion). Furthermore, Eisai will pay double-digit royalties based on sales of the product. Eisai anticipates no changes to its consolidated financial forecast for the period ending March 31, 2026.“We are pleased to collaborate with Eisai in Japan to advance the development of serplulimab in this important market,” said Dr. Jason Zhu, CEO of Henlius. “Serplulimab has demonstrated its potential across multiple tumor types through global clinical development and regulatory approvals, and Japan represents a critical step in its international journey. By combining Henlius’ innovation capabilities with Eisai’s deep local expertise, we aim to support the efficient development of serplulimab and address unmet medical needs for patients in Japan.”“Serplulimab is an anti-PD-1 monoclonal antibody that has been developed with high priority for indications with significant unmet medical needs, including ES-SCLC, and has already obtained approval for multiple indications in China and the EU. We anticipate that it will also become a promising treatment option in Japan for ES-SCLC and non-MSI-high metastatic colorectal cancer, for which development is underway, as well as for other intractable cancers,” said Toshihiko Yusa, Executive Officer and Head of Japan Business at Eisai. “Eisai will make every effort, in cooperation with Henlius, to deliver serplulimab to patients as soon as possible.”* Converted at an exchange rate of USD 1 = JPY 155MEDIA CONTACTSEisai Co., Ltd. Public Relations DepartmentTEL: +81 (0)3-3817-5120Shanghai Henlius Biotech Inc.Janice Hanjiayi_han@henlius.comBella Zhouwenting_zhou@henlius.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Shanghai Henlius Biotech Inc.Venus Hu junyan_Hu@henlius.com About SerplulimabSerplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly® in the EU) is an anti-PD-1 monoclonal antibody first developed by Shanghai Henlius Biotech, Inc. (“Henlius”), and launched in China in 2022. It has been approved by the National Medical Products Administration of China for indications including squamous non-small cell lung cancer, extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma, and non-squamous non-small cell lung cancer, and is the world's first anti-PD-1 antibody to be used as a first-line treatment for ESSCLC. It has been approved for the treatment of ES-SCLC in over 40 markets, including the EU, Southeast Asia (Indonesia, Cambodia, Thailand, Singapore, Malaysia), and South America (Peru). Henlius is actively promoting the broader use of serplulimab both as a standalone product and in combination with other innovative therapies, including those developed in-house and externally. Furthermore, the company is conducting numerous clinical trials worldwide on therapies for conditions where existing anti-PD-1 antibodies have not yet been used, focusing on indications such as lung cancer and gastrointestinal tumors.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe.About Shanghai Henlius Biotech, Inc.Shanghai Henlius Biotech, Inc. (2696.HK) is a global, innovation-driven biopharmaceutical company committed to delivering high-quality, affordable biologic therapies to patients worldwide. The Company focuses on major disease areas including oncology, autoimmune diseases, and ophthalmic diseases. Founded in 2010, Henlius has established an integrated, end-to-end biopharmaceutical platform encompassing global R&D, clinical operations, regulatory affairs, manufacturing, and commercialisation. The Company employs nearly 4,000 people globally and operates across multiple regions, including China, the United States, and Japan. Leveraging the stable cash flow generated from its biosimilar portfolio to support innovation, Henlius is steadily advancing into its “Globalisation 2.0” phase, building a scalable and sustainable global growth model. As of early 2026, Henlius has achieved regulatory approvals for 10 products across 60 countries and regions worldwide, including seven approvals in China. The Company has also reached multiple milestones in major biopharmaceutical markets, with four products approved by the U.S. Food and Drug Administration (FDA) and four products authorized by the European Medicines Agency (EMA), reflecting its globally aligned R&D capabilities, quality systems, and manufacturing standards.Driven by innovation, Henlius has built a diversified, platform-based technology ecosystem through coordinated R&D efforts across Shanghai, the United States, and other regions. Its innovation platforms span immune checkpoint inhibitors, immune cell engager technologies (including multispecific T cell engagers), antibody-drug conjugates (ADCs), and AI-enabled early discovery platforms. The Company currently has more than 50 early-stage innovative assets, approximately 70% of which are expected to be best-in-class, with over 30 clinical trials ongoing globally. Henlius’ core product, serplulimab (trade name: Hetronifly® in Europe), is the world’s first anti–PD-1 mAb approved for first-line treatment of small cell lung cancer and has been approved in more than 40 markets worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope anti-HER2 mAb HLX22—are advancing through global pivotal clinical development. Supported by a biologics manufacturing network with a total capacity of 84,000L and GMP certifications from regulatory authorities in China, Europe, and the United States, Henlius has established a stable global supply system serving six continents. Guided by a patient-centred mission, Henlius remains focused on addressing unmet medical needs and translating scientific innovation into meaningful clinical value and patient access, contributing sustainably to the global biopharmaceutical ecosystem.To learn more about Henlius, visit https://www.henlius.com/en/index.html and connect with us on LinkedIn at https://www.linkedin.com/company/henlius/.References1. Issafras H, Fan S, Tseng C-L, Cheng Y, Lin P, Xiao L, et al. (2021) Structural basis of HLX10 PD1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy. PLoS ONE 16(12): e0257972. https://doi.org/10.1371/journal.pone.02579722. National Cancer Center Japan, Cancer Information Service, Cancer Statistics (Japanese only) https://ganjoho.jp/reg_stat/statistics/stat/cancer/index.html Last accessed: January 2026.3. Sabari, J., Lok, B., Laird, J. et al. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol 14, 549–561 (2017).4. Fujiyoshi K, Yamamoto G, Takenoya T et al. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor. Anticancer Res. 2017;37(1):239- 247.5. Cancer Statistics in Japan-2025 https://www.fpcr.or.jp/pdf/pamphlet/cancer_statistics_2025.pdf (P30) Last accessed: January 2026. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Kawasaki and Tokyo, Japan, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu Japan Limited and JMDC Inc. today announced the commencement of a collaboration aimed at advancing medical care and contributing to the establishment of a sustainable healthcare system in Japan.This collaboration, which began on January 5, leverages JMDC's expertise in utilizing anonymized medical data and Fujitsu Japan's customer base. Fujitsu Japan holds the top share in the Japanese electronic health record (EHR) market for medical institutions. This synergy will accelerate the utilization of medical data by medical institutions and organizations that are part of the healthcare system, while also supporting data-driven management decision-making.This collaboration will see the two companies combine Fujitsu Japan's knowledge in the medical field and advanced technologies including AI, with JMDC's prediction models based on insurance user data and its expertise cultivated through Pep Up, one of Japan's largest personal health record services used by 7.7 million people. This will expand the scope of data utilization from DPC data [1] to comprehensive EHR data. This initiative will further promote the utilization of medical data, contributing to improved management for medical institutions and advanced research for pharmaceutical companies, government agencies, and academia.Going forward, Fujitsu Japan will contribute to the realization of digital hospitals that promote DX in medical institutions, while JMDC will advance initiatives that contribute to "building a sustainable healthcare system through addressing social issues with the power of data and ICT" and "accelerating the societal integration of data."Overview of the collaborationFujitsu Japan will provide Dashboard 360, a solution that enables visualization and analysis of management and clinical data, free of charge [2] to medical institutions that agree to provide anonymized DPC data [3]. Dashboard 360 is offered as part of Fujitsu Limited's Uvance business model, which addresses societal challenges, specifically within the Smart Hospital offering that maximizes hospital operational efficiency and effectiveness. It is a component of the Healthcare Management Platform, a suite of services designed to optimize patient flow [4] in acute care hospitals and support the resolution of management challenges.Dashboard 360 seamlessly integrates with EHRs, allowing for factor analysis of issues such as declining bed occupancy rates and waiting times for hospitalization or surgery, based on information including inpatient care and outpatient conditions leading to hospitalization. It also features a benchmarking function, utilizing data provided by JMDC and DPC data from medical institutions, to support timely decision-making in hospital management.JMDC will collaborate with Fujitsu Japan to anonymize DPC data in a secure environment and provide it to pharmaceutical companies, government agencies, and universities for research purposes. Additionally, by combining this with JMDC's accumulated insurance user data, covering approximately 20 million individuals, the collaboration will visualize the entire patient journey from pre-onset abnormal test results to inpatient treatment and post-discharge prognosis. This will enable early detection of diseases through screening of potential patients, prevention of severe cases by identifying risk factors, and precise evaluation of long-term treatment effects and drug safety in real-world settings, thereby contributing to the improvement of medical quality and efficiency.Figure: Collaboration overviewBackgroundIn Japan, the aging population and increasing medical expenses are pressing concerns. Challenges such as a shortage of healthcare professionals and financial difficulties for medical institutions persist. By leveraging medical data, it is expected that these challenges can be addressed through improved diagnostic accuracy, enhanced operational efficiency, development of new treatment methods, and strengthened regional healthcare collaboration.[1] DPC data:Data used to calculate medical costs based on the patient's diagnosis and treatment content during hospitalization. It includes patient information, diagnoses, surgical procedures, medications used, and is expected to be utilized for analyzing medical quality and hospital management, as well as for formulating healthcare policies.[2] Agreement to provide anonymized DPC data:Fujitsu Japan is entrusted by medical institutions with the creation of anonymized information such as DPC data, and the medical institutions grant Fujitsu Japan permission for secondary use of the created anonymized information.[3] Free of charge:No initial setup or usage fees. A separate license fee for the BI tool included in the service is required.[4] Patient flow:The management of the entire patient process from hospital visit to discharge.About FujitsuFujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuAbout JMDCEstablished in 2002 as a pioneer in the medical big data industry, JMDC possesses proprietary anonymization processing technology and data analysis/aggregation technology. Based on the analysis of over 1.573 billion medical claims data and over 76 million health checkup data (as of March 2025), JMDC provide information services, including support for health promotion programs for payers, drug safety evaluation, and healthcare economics analysis. JMDC is committed to realizing a healthy society through medical data and analytical capabilities, providing a single index for health (Health Age) and web services for health promotion (Pep Up), among others. Find out more: https://www.jmdc.co.jp/en/Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiriesJMDC Inc.JMDC Inc. IR OfficeEmail: jmdc-pr@jmdc.co.jp Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Tokyo and Kawasaki, Japan, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Genesys® Cloud Services, Inc. (Headquarters: Minato-ku, Tokyo; President: Paul Ito Ricci, hereinafter Genesys), a global cloud leader in AI-Powered Experience Orchestration, and Fujitsu Limited (Headquarters: Kawasaki City, Kanagawa Prefecture; President and CEO: Takahito Tokita; hereinafter Fujitsu) which led the implementation of Genesys Cloud, announced the successful transformation of AEON Financial Service Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; President and CEO: Tomoharu Fukayama; hereinafter AEON Financial Service) contact center operations and the completion of its effectiveness evaluation.As part of this contact center transformation initiative, AEON Financial Service deployed Genesys Cloud™, a unified experience orchestration platform. Because of the composability of the Genesys Cloud platform, Fujitsu implemented customizations to meet its unique business requirements, including reporting management and system integrations, and will continue to support maintenance and operations. With over 2,500 seats, this deployment is among the largest of its kind in Japan’s financial sector.AEON Financial Service plans to introduce an “AI Concierge (Voice Bot)” utilizing speech recognition technology. This will allow customers to be guided to the appropriate menu through natural spoken dialogue, eliminating the need for phone keypad input. Furthermore, AEON Financial Service is considering expanding the solution to other contact centers across the AEON Group. Genesys and Fujitsu will continue to support the advancement of contact center systems across the entire AEON Group.Paul Ito Ricci, President of Genesys Japan, commented:"AEON Financial Service is demonstrating how modern experience orchestration can transform customer engagement at scale in a short period.By moving its contact center platform to the cloud, the company has been able to internalize system development and significantly accelerate the speed at which it can deliver more convenient services to address customers’ needs. . We are committed to supporting AEON Financial Service through Genesys Cloud as they utilize AI to deliver innovative, personalized and empathic customer experiences and seamless support for each individual at scale."Masaru Yagi, Executive Vice President, Fujitsu Limited, commented:"We are pleased to announce the successful introduction of Genesys Cloud to enhance the contact center operations for AEON Financial Service. This initiative addresses the crucial and growing need for contact center transformation in recent years. We are confident that this project meaningfully contributes to establishing an operator-first environment where high-quality customer experience can be delivered without added burden. Fujitsu will continue to support the implementation and operation of Genesys Cloud as a solution vendor, leveraging AI and other technologies to support AEON Financial Group and many other companies."BackgroundAEON Financial Service call center is responsible for comprehensive support across a wide array of financial services, including banking, insurance, and loans, in addition to payment services such as AEON Pay, AEON Card, and WAON. A significant challenge for the company was the increase in customer waiting times due to the growing variety of inquiry types and the increasing specialization and segmentation of internal guidance points. Moreover, the conventional on-premises call center system required modernization to effectively support future service expansion.Improvements driven by the contact center operations overhaulFollowing the deployment of Genesys Cloud and the overhaul of its contact center operations, AEON Financial Service has realized the following benefits within the first six months:1. Higher self-service completion ratesBy expanding self-service options within the IVR (Interactive Voice Response) system, the self-completion rate for the menu option that allows customers to report payments after a failed withdrawal improved by 21 percentage points compared to the previous system, helping reduce customer wait times.2. Automated SMS supportBy implementing a mechanism that automatically sends an SMS in response to IVR inquiries, simple questions can now be resolved through self-service. This allows operators to concentrate on more complex tasks.3. Rapid feature enhancements and flexible operationsThe use of a cloud service with the requirement of a low-code functionality enables the speedy deployment of new services and quick changes to the IVR structure. Furthermore, future efforts to bring development in-house will allow for even faster response times.About GenesysGenesys® empowers more than 8,000 organizations worldwide to create the best customer and employee experiences. With agentic AI at its core, Genesys Cloud™ is the AI-Powered Experience Orchestration platform that connects people, systems, data and AI across the enterprise. As a result, organizations can drive customer loyalty, growth and retention while increasing operational efficiency and teamwork across human and AI workforces. www.genesys.com/ja-jpAbout FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiriesGenesys Cloud Services, Inc. Genesys PR Office (Initial Inc.)Contacts: Hirabayashi, Nagaoka, AkiyamaTel: +81-3-5572-7334 Email: genesys_pr@vectorinc.co.jp Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com